Gastroenterology and Hepatology

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Steven Maron, MD, MSc Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven

Host: Jennifer Caudle, DOGuest: Manpreet Mundi, MD Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there’s an urgency to manage patients symptoms, and one option that’s been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kalpesh Thakkar, MD, MSCR Cow’s milk protein allergy is the most common food allergy in infants. And overall, it’s important to know that in general, the incidence of allergy is increasing worldwide. To take a deep dive, join Dr. Charles Turck as he speaks with Dr. Kalpesh Thakkar, Pediatric Gastroenterologist at Memorial Hermann Medical Group in Sugarland, Texas. All trademarks are owned by Société des Produits Nestlé S.A., Vevey,

Host: Jennifer Caudle, DO Guest: Katherine Bennett, MPH, RD, CLEC Caregivers and children often face challenges when trying to find a formula that’s well-tolerated, and the burden of feeding intolerance extends to the healthcare system as well. Find out how blenderized whole food tube feeding whole food tube feeding formulas like Compleat Organic Blends can help address those challenges and benefit pediatric patients with Dr. Jennifer Caudle and Ms. Katherine Bennett, a registered

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gil Melmed, MD, MS The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed,